Rapid Briefs
VV catches the signal early, explains it cleanly, shows the source trail, and tells you what not to overclaim.
Filtered signal trail
Larimar submitted the first module of a rolling BLA for nomlabofusp, a frataxin-replacement candidate for Friedreich's ataxia.
Why now
Friedreich's ataxia has few disease-modifying options and the program is moving from biomarker signal toward FDA review.
Regenxbio says FDA aligned on a path to resubmit Navsunli/RGX-121 for accelerated approval review, but the therapy is not approved.
Why now
FDA has reopened a filing path after the program's regulatory outlook had narrowed.
A new FDA draft guidance and recent reversals suggest the biggest bottleneck in gene therapy may no longer be the science alone. It may be the approval process itself.
Why now
Draft guidance and recent reversals suggest the rare-disease rulebook is changing in real time.
